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ABSTRACT 
 
Poultry is a major source of protein in sub-Saharan Africa and many other lower-income 
regions. Newcastle disease virus (NCDV) comprises a significant threat toward poultry 
production. While NCDV vaccines are routinely used in developed countries, those used 
in sub-Saharan Africa are mostly imported and are not specific to locally circulating 
strains. Indeed, the lack of rapid, field-based NCDV detection and the absence of cost-
effective production methods for pure, strain-specific vaccines hampers efficient poultry 
production throughout these regions. This remains a major problem for both subsistence 
and commercial farming. The aim for this study was firstly, to develop a field-based 
isothermal PCR assay for NCDV detection that employed a portable instrument and real-
time data transfer application. Secondly, to use the nucleic acid sequence data obtained 
from field isolates to develop a protocol compatible with rapid emergency vaccine 
production for NCDV. To achieve this, the isothermal PCR detection assay was applied 
to field isolates from suspected NCDV outbreaks on commercial poultry farms in 
KwaZulu-Natal, South Africa, while for the vaccine development, the NCDV matrix 
gene of one of the isolates was sequenced and used to design primers for the recombinant 
cloning of this antigen into an adenoviral vector. This ‘vaccine vector’ and a control 
adenoviral vector were each amplified in 293T cells and then used to infect both 293T 
cells as a production cell line and chicken embryo fibroblasts (CEF) as a preliminary 
model of the target host. Western blotting confirmed the successful expression of the V5 
epitope tag by the control vector in both cell lines, which established the compatibility 
of the adenovirus vector as an appropriate carrier of the target antigen. Mass spectrometry 
confirmed expression of the NCDV matrix protein by the vaccine vector in both cell 
lines. In conclusion, the improved turnaround time from detection to the production of 
the vaccine antigen was under 6 weeks. The approach described here provides a rapid 
and cost-effective protocol for both the pathogen detection on-site and the production of 
pure vaccine antigens specific to an emerging field strain of NCDV within lower-income 
regions.  
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INTRODUCTION 
 
Poultry production is increasingly recognized as one of the possible solutions to 
malnutrition, food security and poverty in low- and middle-income countries (LMICs) 
[1, 2, 3]. Newcastle disease (NCD) is one of the most fatal diseases of birds and a major 
threat to the poultry industry worldwide [4]. The causative agent is the Newcastle disease 
virus (NCDV), which is a single-stranded, non-segmented and negative-sense RNA virus 
that belongs to the Paramyxoviridae family [5]. The NCDVs are classified into three 
pathotypes based on the severity of the disease they cause. The lentogenic pathotypes are 
of low virulence [6], the mesogenic pathotypes are moderately pathogenic, thus causing 
significantly lower mortality [6], while velogenic pathotypes are highly fatal and cause 
the severest form of NCD [7]. 
 
Vaccination remains the primary and most effective strategy for the prevention and 
management of NCDV [8]. In general, live vaccines are often used for the prevention of 
NCDV because they exhibit mild symptoms after immunisation [9]. However, live 
NCDV vaccines frequently exert adverse effects, with respiratory disease and reduced 
egg production being the most frequently reported symptoms [10]. Live vaccines may 
also revert to virulence, leading to clinical disease and loss of production.  
 
Owing to the size of the global poultry industry, which includes rural subsistence chicken 
farming in LMICs, there is consequently a high demand for NCD vaccines. However, 
velogenic field strains show high genetic diversity, and while cross-protection is often 
present to some degree, there is no guarantee that commercially available vaccines will 
confer sufficient (or any) immunity [11]. Most of the NCD vaccines used in sub-Saharan 
Africa are imported from outside the continent, and are, therefore, not based on strains 
relevant to the region. In Indonesia, sequence divergence between the field and vaccine 
strains (Hitchner B1 and LaSota) was shown to be the cause of a severe NCDV outbreak 
that led to 70% mortality among the vaccinated birds [12]. The few vaccines that are 
produced locally are generally impure, containing both viral structural and non-structural 
proteins, which prevent differentiation between vaccinated and infected animals (DIVA) 
based on immunological testing.  
 
Human adenoviruses (Ads) are well suited for use as recombinant vaccine vectors. This 
is because Ads can efficiently infect a wide variety of cell types, have the capacity to 
grow to high titres in vitro, have high levels of transgene expression, lack integration into 
the host genome and show genetic stability [13]. Adenovirus vaccines have also been 
shown to induce potent immune responses in various cell lines [14] as well as in chickens 
[15], and the efficacy of Ad-based vector vaccines in protecting chickens against virulent 
strains of avian influenza has been demonstrated [16]. The aim for this study was to 
develop and use a field detection assay combined with an adenovirus vector-based 
method for outbreak-specific vaccine production to enable quick turnaround from NCDV 
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MATERIALS AND METHODS 
 
Virus detection, vaccine vector design and sequence verification 
Sample collection and Viral RNA extraction 
Twenty-nine NCDV samples were collected by Rainbow Farms (Pty) Ltd (KwaZulu-
Natal, South Africa) during suspected outbreaks in their poultry stock in 2016. These 
samples were isolated within a single month from different farms in KwaZulu-Natal and 
were likely of the same strain, with a mortality rate of 15–20%. All samples tested 
positive for NCDV based on PCR analysis performed by Rainbow Farms. The NCDV 
samples mentioned above were used in the current study. Viral RNA was extracted from 
a 140 µL aliquot of each of the 5 mL of inactivated NCDV samples with the QIAamp 
Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) and eluted in 60 µL elution buffer 
according to the manufacturer’s instructions. The RNA samples were stored at -80°C for 
later usage. 
 
Isothermal PCR design and Virus detection 
Isothermal PCR  is a rapid nucleic acid amplification assay which takes thirty (30) to 
sixty (60) minutes at an isothermal temperature of 60- 65ºC (17). For the detection of 
NCDV, the primers designed by Tian et al.  [17] were used as described for isothermal 
PCR-based detection on an Axxin T16 isothermal PCR instrument (Axxin, Fairfield, 
VIC, Australia), using a NCDV sample that had previously been characterized as a 
positive control and buffer only as the negative control. The Axxin instrument was pre-
loaded with an inhouse developed ‘ImPulse’ software application capable of uploading 
field results into a designated central database in real-time. Analysis of the data is then 
carried out by experienced personnel situated anywhere in the world through verified 
login details provided. 
 
Target gene sequencing and primer design for cloning 
Among the samples tested by isothermal PCR, one sample was randomly chosen for 
next-generation sequencing. The viral RNA extracted from this sample was reverse 
transcribed into cDNA with the Transcriptor First Strand cDNA Synthesis Kit (Roche 
Life Science, Mannheim, Germany) according to the manufacturer’s instructions. The 
whole genome including the NCDV matrix gene was sequenced in-house using the Ion 
Torrent ™ Personal Genome Machine (PGM™) next generation sequencer (Thermo 
Fisher Scientific, Johannesburg, South Africa).  
 
PCR was chosen to amplify the longest possible matrix gene fragment for cloning 
purposes. The NCBI Primer-BLAST tool was used to design six primer sets (Table S1- 
Supplementary data) for amplification of the NCDV matrix gene from the isolated viral 
RNA, based on apparent conserved sites across the sequenced matrix gene (Fig. S1- 
Supplementary data) and the matrix genes of NCDV strains deposited in the NCBI 
database. Based on this analysis, the forward primer MF8A (5ʹ-
ATAGGATCCAGCGCCTTGAC-3ʹ) and the reverse primer MR5 (5ʹ- 
GTATTTGGCAAGGGTGTGCC-3ʹ) were selected, as this primer set amplified the 
longest fragment (956bp) between conserved sites compared to the other possible primer 
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Recombinant cloning 
To amplify the NCDV matrix gene fragment for subsequent cloning, the KAPA HiFi 
HotStart ReadyMix PCR Kit (KAPA Biosystems, Cape Town, South Africa) was used 
according to the manufacturer’s recommendations. The PCR reaction comprised 12.5 µL 
of 2× KAPA HiFi HotStart ReadyMix, 0.6 µM each of the MF8A and MR5 primers and 
11 µL of cDNA prepared from the viral RNA (total volume per reaction, 25 µL). The 
PCR was performed with the Roche LightCycler 480 instrument using the recommended 
cycling parameters with the annealing temperature maintained at 57ºC. The PCR 
products were resolved by 1% agarose gel electrophoresis to confirm amplification and 
were extracted from the agarose gel with the GeneJET Gel Extraction Kit (Thermo Fisher 
Scientific).  
 
The amplified NCDV matrix gene fragment was cloned into an adenoviral expression 
vector (pAd/CMV/V5-DEST) using the pAd/CMV/V5-DEST Gateway Vector Kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. Briefly, a 
blunt-end PCR product (to ensure directional cloning) was generated from the 
amplified matrix gene fragment with appropriately designed primers (MBf: 5ʹ-
CACCATGTATAGGATCCAGCGCCTTGAC-3ʹ, MBr: 5ʹ-
GTATTTGGCAAGGGTGTGCC-3ʹ). The gel-cleaned blunt-end PCR product and the 
pENTR/D TOPO vector (Thermo Fisher Scientific) were mixed together at room 
temperature for 5 min. This mixture was transformed into competent E. coli cells. 
Plasmid DNA was isolated from the positive transformants and used in the LR 
recombination reaction with the pAd/CMV/V5-DEST vector. The LR recombination 
reaction mixture was then transformed into competent E. coli cells, followed by 
purification of the adenoviral vector from the positive transformants.  
 
Recombinant adenovirus propagation 
The purified recombinant adenoviral plasmid DNA was first digested with the PacI 
enzyme (Thermo Fisher Scientific) according to the manufacturer’s instructions before 
transfection into the human embryonic kidney (293T) cells (Thermo Fisher Scientific). 
Approximately 5 × 105 293T cells were seeded per well in a 6-well plate containing 2 
mL/well of Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Kempton Park, South 
Africa) supplemented with 10% foetal bovine serum (FBS; Thermo Fisher Scientific) 
and 0.05 mg/L gentamicin (Lonza). After a 24-h incubation, the cells were transfected 
with the digested adenoviral vector using Lipofectamine 2000 (Thermo Fisher 
Scientific). Once a cytopathic effect of 80% was observed, the adenovirus was harvested 
from the cells using the freeze and thaw method. The resultant viruses were then stored 
at −80ºC. The Ion PGM system was used to confirm the sequence of the target NCVD 
matrix gene insert in the recombinant adenoviral vector.  
 
Expression of the control and recombinant adenovirus vectors in 293T cells and 
chicken embryo fibroblasts (CEFs) 
Preparation and infection CEFs 
Chicken Embryo Fibroblasts (CEFs) were prepared from 11-day-old chicken eggs 
according to a standard protocol [18]. These cells were then incubated at 37⁰C with 5% 
CO2 at a set humidity of 95%. At the third passage, the cells were visualised with an 
Olympus light microscope BX53 (Olympus Corporation, Tokyo, Japan) using phase 
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contrast at 10× magnification. As a preliminary investigation of the infectivity of 
adenovirus towards the targeted host (chicken), a control adenovirus vector 
(pAd/CMV/V5-GW/lacZ; Thermo Fisher Scientific) and the recombinant adenovirus 
vector (the “vaccine vector”) were used to infect the CEFs.  Approximately 3 × 106 CEFs 
were suspended in 10 mL DMEM supplemented with 10% FBS and seeded per 10-cm 
tissue culture plate followed by incubation as before. At 70% confluency, cells in one set 
of plates were infected with the purified control adenovirus (pAd/CMV/V5-GW/lacZ) 
containing theV5 epitope, while the cells in the other set of plates were left uninfected 
(negative control). Cells were incubated for 4 days, following which, the cells were 
visualised by light microscopy to check for any signs of cytopathic effect following viral 
infection.  
 
The 293T cells were also infected with the control vector by following the same infection 
protocol used for the CEFs. 
 
Western blot analysis of the expression of the control adenovirus vector in 293T 
cells and CEFs 
To test the compatibility of the adenovirus vector with the CEF primary cell line, the 
expression of the V5 epitope in infected cells was determined through western blot 
analysis. Briefly, after cell incubation for 4 days following infection, total cell lysates 
were prepared using lysis buffer (1 M Tris pH 8.0, 0.5 M EDTA, 1 M KCl, 0.5% Triton 
X-100 and 1× protease inhibitor) and subjected to SDS-PAGE on a Bolt 4–12% Bis-Tris 
Plus gel (Thermo Fisher Scientific) and then the proteins were transferred to an Immune-
Blot PVDF Membrane (Bio-Rad, Johannesburg, South Africa). The membrane was 
blocked in PBS-T (1× PBS pH 7.4, 0.1% (v/v) Tween 20) containing 5% non-fat dry 
milk (Bio-Rad) for 2 h at 4⁰C. The membrane was rinsed three times with PBS-T and 
incubated overnight at 4⁰C with mouse anti-V5 (AbD Serotec, Hercules, CA, USA) 
diluted 1:2,000 in 5% milk PBST. After three rinses with PBS-T, the membrane was 
incubated with 1:2,000 goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, 
Heidelberg, Germany) in 5% milk PBS-T for a 1 h at room temperature. The 
chemiluminescent signal was detected by applying the Clarity ECL substrate (Bio-Rad) 
and exposing the membrane to UV light. Images were captured with the Gel Doc XR+ 
documentation system (Bio-Rad). The same procedure was followed to analyse the 
expression of the V5 epitope in the 293T cells. 
 
Mass spectrometry analysis of the expression of the recombinant adenovirus vector 
(Ad-recNCDV) in CEFs 
Following confirmation of the expression of the control adenovirus vector in 293T cells 
and CEFs using western blots, expression of the NCDV matrix protein from the Ad-
recNCDV was analysed by mass spectrometry for the purpose of establishing a rapid 
emergency vaccine development protocol. Using standard procedures, protein was 
extracted from the non-infected CEFs and 293T cells (negative controls) and the CEFs 
infected with the vaccine vector. Protein samples (20 µg each) were purified of salts and 
detergents with MagReSyn HILIC microparticles (ReSyn Biosciences, Pretoria, South 
Africa) with on-particle protein digestion using sequencing-grade modified trypsin 
(Promega, Madison, WI, USA). The resultant peptides were analyzed with a Dionex 
UltiMate 3000 RSLC system (Thermo Fisher Scientific) coupled to an AB Sciex 
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TripleTOF 6600 mass spectrometer (AB Sciex, Singapore). Mass spectrometry (MS) 
data were searched with the SearchGUI interface [19] using the X!Tandem [20], MS-
GF+ [21] and Comet [22] search engines. The target database was generated by adding 
the sequences of the NCDV matrix protein and common contaminants to the whole 
proteomes of dsDNA viruses listed in the UniProt database. Decoy sequences were 
created by reversing all the sequences in the target database in SearchGUI. A 1% false 
discovery rate cut-off was applied at the PSM (peptide-spectrum match) and protein 
level. 
 
RESULTS AND DISCUSSION 
 
Field-based virus detection, vaccine vector design and sequence verification  
The isothermal PCR   successfully detected NCDV in the 29 field cases, previously 
confirmed positive using a conventional PCR assay. The results on the axxin instrument 
are shown in a graph format where a sigmoidal curve shows that the sample tested is 
NCDV positive, while a straight line shows negative results. Only three of the samples 
tested with the isothermal PCR are shown in Fig.1 and these samples were confirmed to 
be NCDV positive.    The total time for sample preparation and virus detection, which 
included the 30-minute sample run on the Axxin T16 instrument, was less than 90 min. 




Figure 1:  Newcastle disease samples were detected by isothermal PCR targeted 
towards the matrix gene. (A) Fluorescence signal over time during 
isothermal PCR of the positive control (green), the field samples (red, 
yellow and blue) and the negative control (black). (B) The second 
derivative plot of the data in (A) to pinpoint the exact time of 
identification (peaks) within the 30-minute assay run 
 
Antibodies against the NCDV hemagglutinin-neuraminidase (HN), fusion glycoproteins 
and matrix gene products are produced following infection with NCDV [23]. The 
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antibodies formed against each of these proteins, particularly HN, have been used 
successfully to protect chickens against virulent NCDV strains [24]. For the present 
study, the matrix gene was, however, chosen as the detection marker and vaccine antigen 
since it is the most widely used detection target for both immunological and molecular 
tests (such as ELISA and PCR). To validate our isothermal PCR method, it had to be 
comparable with the methods commonly used for the detection of NCDV. The same 
method developed here for the matrix gene could later be adapted toward the more 
immunologically protective HN and fusion glycoprotein genes, either singly or in 
combination for maximum potency as a vaccine. However, using the latter two genes as 
a model from the beginning would have resulted in incongruent validation of the 
detection method. 
 
Expression of the adenovirus control and vaccine vectors in CEFs 
Before a vector can be used as a carrier of the gene of interest, it is important to verify 
whether it can infect the chosen production cell line as well as the targeted host primary 
cell line. In pursuit of this objective, CEFs were prepared from chicken embryos (Fig. 2) 
as a preliminary model of the eventual vaccine recipient (chickens). Microscopy 
confirmed that the fibroblasts were viable and had the expected morphology, without any 





Figure 2:  Chicken embryo fibroblasts prepared from an 11-day-old chicken 
embryo and used for transfection with the recombinant adenovirus 
vaccine vector. The resulting fibroblasts remained viable after 




 https://doi.org/10.18697/ajfand.95.18880  16949 
The expression of adenovirus genes in 293T cells has already been reported [25]; 
therefore, this was performed as a confirmatory step. However, expression of the 
adenovirus genes in the CEFs was analysed to confirm the suitability of using an 
adenovirus vector in chickens as the eventual vaccine recipient. The expression of the 
V5 epitope as a control experiment in both 293T cells and CEF confirmed that the 
adenovirus is a suitable delivery vector for chickens (Figure 3). Given that 293T cells 
contain the E1 replication factor, expression of the V5 epitope was higher, confirming 
that 293T cells can be used as a production cell line. Expression of the V5 epitope was 
much weaker in CEFs as these cells lack the E1 gene thus rendering adenovirus 




Figure 3:  Western blot analysis of the control adenovirus vector V5 epitope in 
293T cells and CEFs. Lane 1, uninfected CEFs; lane 2, CEFs infected 
with the adenovirus vector; lane 3, uninfected 293T cells; and lane 4, 
293T cells infected with the adenovirus vector 
 
Expression of the NCDV matrix gene by the vaccine vector was analysed in the CEFs. 
Since it is critical that expression of the gene of interest be directly confirmed so as to 
inform decision-making during the vaccine development process, mass spectrometry 
(MS) was used. Figure 4 shows regions in the matrix protein that were digested by the 
trypsin enzyme to form the peptides analysed by MS.  Five peptides were identified from 
viruses propagated in the 293T cells with a NCDV matrix protein coverage of 19% 
(Table 1). Most importantly, MS also confirmed the expression of the NCDV matrix 
gene by the recombinant adenovirus in the CEFs, where four peptides were identified 
with a NCDV matrix protein (Table 1). Generally, identification of peptide sequences in 
one region of a single protein after trypsin digestion of the protein of interest is enough 
to positively identify such a protein. In this case, four different pieces of peptide 
sequences were identified. These 4 pieces of peptide sequences were equal to 16% of the 
total protein length, hence the 16% coverage. This conclusively identifies the matrix 
protein as being present in the developed vaccine vector.  Therefore, these percentage 
coverages are significant enough to consider the matrix protein to be expressed in both 
cell lines. As anticipated, non-infected CEFs contained none of the peptides identified in 
the matrix protein. A single unique peptide is usually enough to identify a specific protein 
presence. In this case, no less than four (4) fragments were identified in 293T cells and 
CEFs that were uniquely those of the matrix gene protein product. These results indicate 
that the recombinant adenovirus vector could function as a vaccine production system 











Figure 4:  The NCDV matrix protein sequence cloned into the recombinant 
adenovirus vector. The underlined amino acid sequence shows where 
the protein was cleaved during on-particle protein digestion using 
trypsin. The highlighted regions indicate the peptides identified by mass 
spectrometry  
 
Suitability of the emergency vaccine production protocol 
Outbreaks caused by NCDV frequently lead to significant economic losses to the poultry 
industry worldwide [4]. However, current commercial vaccines are not always designed 
based on strains relevant to all regions [9, 26]. The current work, therefore, focused on 
developing a strategy for the rapid production of emergency vaccines specific to outbreak 
strains emerging in LMICs. Critical to such a strategy is the speed at which the outbreak 
strain is identified, and a response vaccine is produced. As shown in Figure 5, the entire 
process described here from initial field identification of the ‘outbreak’ strain through to 
the production of the Ad-based vaccine would take a maximum of 6 weeks, which is a 
significant improvement over conventional strategies that can take 6–8 months [27].  
 
The proposed strategy is cost-effective [28] and can be readily implemented in the sub-
Saharan African region. These emergency vaccines would be designed based on the 
actual isolated field strains and are, therefore, likely to provide more effective immune 
protection; while vaccination remains the most successful strategy for the prevention and 
management of NCD, commercial vaccines are typically at most only mildly effective 
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Figure 5:  Schematic diagram of the proposed strategy for directed NCD 
emergency vaccine production, describing the workflow and validation 
steps from sample isolation to vaccine formulation. The entire process 
takes less than 6 weeks  
 
Considering that an emergency vaccine would not have the opportunity to undergo 
clinical trials before being applied in an emergency situation, the emphasis in the current 
work was equally placed on the use of a specific target antigen and the rapid turnaround 
of emergency vaccine production. The emergency vaccine was designed using the human 
recombinant adenovirus vector, since such vectors are known for their ability to infect a 
wide variety of cell types, to grow to high titres in vitro, to have high levels of transgene 
expression and their inability to integrate into the host genome [13]. To aid the universal 
application of our strategy, mass spectrometry was used instead of western blotting to 
confirm the expression of the target antigen by the recombinant adenovirus, because 
mass spectrometry is not dependent on the availability of commercial antibodies towards 
the antigen of interest. While mass spectrometry may not necessarily be cheap or readily 
available, such analysis can be performed by designated laboratories at a relatively 
reasonable cost. The combination of the accuracy and fast turnaround of mass 
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In this model, once an emerging strain is identified, an Ad-based platform allows for the 
differentiation between vaccinated and infected animals (DIVA) [29]. Ad-based vaccine 
development allows for ease of genetic manipulation and safety for production in cell 
lines [25, 30]. Furthermore, adenovirus vector-based vaccines with suitable gene 
products have also been shown to protect chickens against virulent strains of avian 
influenza [16]. Although the current study focused on developing an emergency vaccine 
design and production model and did not investigate the level of immune protection 
provided by the resultant product, in vivo studies/clinical trials of the recombinant 
adenovirus vaccine could be performed in live chickens to confirm protection from 
NCDV infection. However, given that the matrix gene is not necessarily a highly 
effective immunogenic factor in NCDV protection, more functional genes such as the 
HN and F genes could be inserted in future. The final formulation of the vaccine could 
also include adjuvants such as short and long-term initiation factors to further improve 




This study addresses the current mismatch between existing commercial vaccines and 
the vaccines required to target emerging NCDV strains, particularly in LMICs. 
Importantly, this vaccine design approach will likely also prove suitable for other poultry 
viral diseases besides NCDV. Overall, this new strategy could enable quicker turnaround 
times for disease management, and it could equip developing nations with the capacity 
to produce vaccines specific to pathogenic strains of NCDV emerging within their 
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Table 1: Mass spectrometry identification of the NCDV matrix protein expressed 
by the purified recombinant adenovirus (the “vaccine vector”) in 293T 








Matrix protein coverage (%) 19 16 - 
No. of unique peptides identified 5 4 - 
Peptides identified (+) 
N-APEKIPGSGTLEYK-C + + - 
N-VNFVSLTVVPK-C + + - 
N-ILWSQTACLR-C + - - 
N-IIIQAGTQR-C + + - 
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